Anika Therapeutics (ANIK) Competitors $8.83 +0.19 (+2.20%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$8.84 +0.01 (+0.11%) As of 08/15/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ANIK vs. ANVS, CERS, OSUR, UTMD, WST, COO, ALGN, MMSI, ICUI, and HAEShould you be buying Anika Therapeutics stock or one of its competitors? The main competitors of Anika Therapeutics include Annovis Bio (ANVS), Cerus (CERS), OraSure Technologies (OSUR), Utah Medical Products (UTMD), West Pharmaceutical Services (WST), Cooper Companies (COO), Align Technology (ALGN), Merit Medical Systems (MMSI), ICU Medical (ICUI), and Haemonetics (HAE). These companies are all part of the "medical" sector. Anika Therapeutics vs. Its Competitors Annovis Bio Cerus OraSure Technologies Utah Medical Products West Pharmaceutical Services Cooper Companies Align Technology Merit Medical Systems ICU Medical Haemonetics Annovis Bio (NYSE:ANVS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends. Does the media favor ANVS or ANIK? In the previous week, Annovis Bio had 1 more articles in the media than Anika Therapeutics. MarketBeat recorded 7 mentions for Annovis Bio and 6 mentions for Anika Therapeutics. Annovis Bio's average media sentiment score of 0.86 beat Anika Therapeutics' score of 0.59 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in ANVS or ANIK? 15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 9.6% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher valuation & earnings, ANVS or ANIK? Annovis Bio has higher earnings, but lower revenue than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$24.59M-$2.04-1.34Anika Therapeutics$119.91M1.06-$56.38M-$4.15-2.13 Which has more volatility and risk, ANVS or ANIK? Annovis Bio has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Is ANVS or ANIK more profitable? Annovis Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -48.99%. Anika Therapeutics' return on equity of -10.97% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -206.01% -158.26% Anika Therapeutics -48.99%-10.97%-8.51% Do analysts recommend ANVS or ANIK? Annovis Bio presently has a consensus target price of $18.00, suggesting a potential upside of 559.34%. Anika Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 103.85%. Given Annovis Bio's higher probable upside, research analysts clearly believe Annovis Bio is more favorable than Anika Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Anika Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryAnnovis Bio beats Anika Therapeutics on 10 of the 16 factors compared between the two stocks. Get Anika Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIK vs. The Competition Export to ExcelMetricAnika TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$124.57M$3.10B$5.67B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-2.1320.7630.8025.13Price / Sales1.06364.18466.77115.19Price / Cash90.5842.3037.4059.05Price / Book0.868.659.096.18Net Income-$56.38M-$54.65M$3.26B$265.11M7 Day Performance8.88%6.56%7.31%4.20%1 Month Performance-21.09%7.53%5.43%1.99%1 Year Performance-65.53%13.69%30.59%23.75% Anika Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIKAnika Therapeutics4.3729 of 5 stars$8.83+2.2%$18.00+103.9%-65.4%$124.57M$119.91M-2.13300ANVSAnnovis Bio2.6679 of 5 stars$2.82+10.6%$18.00+538.3%-69.2%$49.69MN/A-1.313News CoverageEarnings ReportGap UpCERSCerus3.2757 of 5 stars$1.25+2.9%$3.50+181.1%-43.4%$231.96M$180.27M-12.45290Positive NewsOSUROraSure Technologies2.4866 of 5 stars$2.79+0.4%$3.00+7.5%-33.0%$203.32M$185.83M-4.16840UTMDUtah Medical Products2.7815 of 5 stars$56.25-0.1%N/A-18.7%$182.91M$40.90M15.04180Positive NewsWSTWest Pharmaceutical Services4.6994 of 5 stars$240.40-0.2%$320.71+33.4%-15.9%$17.33B$2.89B35.9910,600News CoveragePositive NewsAnalyst RevisionCOOCooper Companies4.0215 of 5 stars$70.88+0.8%$96.73+36.5%-20.4%$14.06B$3.90B34.4116,000News CoveragePositive NewsALGNAlign Technology4.9466 of 5 stars$134.82-3.6%$215.00+59.5%-39.5%$10.14B$4.00B22.7420,945Positive NewsBuyback AnnouncementMMSIMerit Medical Systems4.8097 of 5 stars$84.04-1.8%$107.00+27.3%-5.6%$5.07B$1.36B42.667,400News CoverageInsider TradeICUIICU Medical4.3409 of 5 stars$108.10-4.2%$190.33+76.1%-23.5%$2.79B$2.38B-71.1215,000News CoverageAnalyst UpgradeInsider TradeHigh Trading VolumeHAEHaemonetics4.9241 of 5 stars$52.55-2.7%$85.18+62.1%-27.2%$2.60B$1.36B16.073,023 Related Companies and Tools Related Companies Annovis Bio Alternatives Cerus Alternatives OraSure Technologies Alternatives Utah Medical Products Alternatives West Pharmaceutical Services Alternatives Cooper Companies Alternatives Align Technology Alternatives Merit Medical Systems Alternatives ICU Medical Alternatives Haemonetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIK) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access